Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7268178 | 0.74 | CYP11B1 (0.34) | CYP11B1CYP11B2 | |
| SCHEMBL9491037 | 0.73 | ALDH1A1 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL584685 | 0.71 | CYP11B1 (0.40) | CYP11B1CYP11B2 | |
| SCHEMBL3849472 | 0.69 | CYP11B1 (0.31) | CYP11B1CYP11B2 | |
| SCHEMBL5326782 | 0.69 | BRD4 (0.32) | CYP11B1CYP11B2 | |
| SCHEMBL17242662 | 0.69 | HSD17B10 (0.34) | CYP11B1CYP11B2 | |
| SCHEMBL7478574 | 0.68 | ALDH1A1 (0.39) | — | |
| SCHEMBL9571803 | 0.68 | ALDH1A1 (0.31) | CYP11B1CYP11B2 | |
| SCHEMBL9236142 | 0.67 | CYP11B1 (0.32) | CYP11B1CYP11B2 | |
| SCHEMBL8390054 | 0.66 | ATM (0.35) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1681290-B9 | Imidazole derivatives, production method thereof and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-1681290-B1 | Imidazole derivatives, production method thereof and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2011-11-16 | — | — | EP | disclosed |
| US-20110263595-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2011-10-27 | — | — | US | disclosed |
| US-7141598-B2 | Imidazole derivatives, production method thereof and use thereof | TAKEDA PHARMACEUTICAL COMPANY, LTD. (JP) | 2006-11-28 | — | — | US | disclosed |
| EP-1681290-A2 | Imidazole derivatives, production method thereof and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2006-07-19 | — | — | EP | disclosed |
| EP-1334106-B1 | IMIDAZOLE DERIVATIVES, PRODUCTION METHOD THEREOF AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-6989383-B1 | Method of treating cancer | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-01-24 | — | — | US | disclosed |
| US-20050137207-A1 | Method of treating cancer | ROSEN NEAL (US) | 2005-06-23 | — | — | US | disclosed |
| US-20040033935-A1 | Novel imidazole derivatives, production method thereof and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-19 | — | — | US | disclosed |
| US-6693123-B2 | (4-(3-PYRIDYLAMINOMETHYLENE)-2-PHENYLBENZOYL)-N -METHYLMETHIONINE, METHYL ESTER FOR EXAMPLE; RESTENOSIS, HYPERPLASIA | UNIVERSITY OF PITTSBURGH | 2004-02-17 | — | — | US | disclosed |
| US-5972942-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-10-26 | — | — | US | disclosed |
| US-5891889-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-04-06 | — | — | US | disclosed |
| US-5856326-A | ANTITUMOR, ANTICANCER AGENTS | MERCK & CO., INC. (US) | 1999-01-05 | — | — | US | disclosed |
| EP-0820445-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-01-28 | — | — | EP | disclosed |
| WO-1997038664-A2 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-10-23 | — | — | WO | disclosed |
| US-5576293-A | TETRAPEPTIDES, ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1996-11-19 | — | — | US | disclosed |
| WO-1996030343-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0338939-B1 | HISTAMINE DERIVATIVE, PROCESS FOR HIS PREPARATION AND HIS THERAPEUTIC APPLICATION | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1993-01-27 | — | — | EP | disclosed |
| US-5034539-A | Histamine derivative, process for preparing it and its therapeutic use | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1991-07-23 | — | — | US | disclosed |
| EP-0338939-A1 | Histamine derivative, process for his preparation and his therapeutic application | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1989-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033935-A1 | Novel imidazole derivatives, production method thereof and use thereof | CYP17A1, CYP21A2, CYP19A1 | CYP11B1 12/4885CYP11B2 21/4885 |
| US-20110263595-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, NTRK1, PRKDC | CYP11B1 2481/4885CYP11B2 2915/4885 |
| US-20050137207-A1 | Method of treating cancer | FNTA, GGT1, NTPCR | CYP11B1 515/4885CYP11B2 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.